Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
The latest announcement is out from Oxford BioDynamics ( (GB:OBD) ).
Oxford BioDynamics Plc announced a leadership change with the resignation of CEO Dr. Jon Burrows and the appointment of Iain Ross as Executive Chairman, subject to a successful equity fundraise. This transition comes as the company seeks additional funding, exploring a potential £4 million equity raise to support its operations. The move is strategic for sustaining the company’s market position and ensuring business continuity, with implications for future growth and stability. The company has appointed Oak Securities as a joint broker, which will make a cornerstone investment as part of the potential equity raise.
More about Oxford BioDynamics
Oxford BioDynamics Plc is an international biotechnology company focused on advancing personalized healthcare through precision clinical diagnostic tests. The company offers the EpiSwitch® PSE (Prostate Screening Test) and EpiSwitch® CiRT (Checkpoint Inhibitor Response Test), which improve predictive accuracy for prostate cancer and immuno-oncology treatments, respectively. Their technology is based on the proprietary EpiSwitch® 3D genomic biomarker platform, with potential applications across oncology, neurology, inflammation, hepatology, and animal health.
YTD Price Performance: -95.71%
Average Trading Volume: 4,507,524
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £3.8M
Find detailed analytics on OBD stock on TipRanks’ Stock Analysis page.
